These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 25180754)

  • 21. Controversies in prostate cancer radiotherapy: consensus development.
    Lukka H; Warde P; Pickles T; Morton G; Brundage M; Souhami L;
    Can J Urol; 2001 Aug; 8(4):1314-22. PubMed ID: 11564274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ACR appropriateness Criteria® early-stage non-small-cell lung cancer.
    Videtic GM; Chang JY; Chetty IJ; Ginsburg ME; Kestin LL; Kong FM; Lally BE; Loo BW; Movsas B; Stinchcombe TE; Willers H; Rosenzweig KE;
    Am J Clin Oncol; 2014 Apr; 37(2):201-7. PubMed ID: 25180631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACR appropriateness Criteria® advanced stage endometrial cancer.
    Elshaikh MA; Yashar CM; Wolfson AH; Cardenes HR; Erickson B; Jhingran A; Jolly S; Kidd E; Lee LJ; Mayr NA; Moore D; Rao GG; Small W; Varia MA; Wahl AO; Yuh W; Gaffney DK;
    Am J Clin Oncol; 2014 Aug; 37(4):391-6. PubMed ID: 24977691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACR Appropriateness Criteria
    ; Coakley FV; Oto A; Alexander LF; Allen BC; Davis BJ; Froemming AT; Fulgham PF; Hosseinzadeh K; Porter C; Sahni VA; Schuster DM; Showalter TN; Venkatesan AM; Verma S; Wang CL; Remer EM; Eberhardt SC
    J Am Coll Radiol; 2017 May; 14(5S):S245-S257. PubMed ID: 28473080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACR Appropriateness Criteria® definitive therapy for early-stage cervical cancer.
    Small W; Strauss JB; Jhingran A; Yashar CM; Cardenes HR; Erickson-Wittmann BA; Gullett N; Kidd E; Lee LJ; Mayr NA; Moore D; Puthawala AA; Rao GG; Varia MA; Wahl AO; Wolfson AH; Yuh W; Gaffney DK
    Am J Clin Oncol; 2012 Aug; 35(4):399-405. PubMed ID: 22810416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A systematic overview of radiation therapy effects in prostate cancer.
    Nilsson S; Norlén BJ; Widmark A
    Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ACR Appropriateness Criteria(®) Aggressive Nonmelanomatous Skin Cancer of the Head and Neck.
    Koyfman SA; Cooper JS; Beitler JJ; Busse PM; Jones CU; McDonald MW; Quon H; Ridge JA; Saba NF; Salama JK; Siddiqui F; Smith RV; Worden F; Yao M; Yom SS
    Head Neck; 2016 Feb; 38(2):175-82. PubMed ID: 26791005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil.
    ; Yeung AR; Garg MK; Lawson J; McDonald MW; Quon H; Ridge JA; Saba N; Salama JK; Smith RV; Yom SS; Beitler JJ;
    Head Neck; 2012 May; 34(5):613-6. PubMed ID: 22250010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer.
    Daly T
    World J Urol; 2020 Mar; 38(3):565-591. PubMed ID: 30850855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
    Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.
    Cox JD; Gallagher MJ; Hammond EH; Kaplan RS; Schellhammer PF
    J Clin Oncol; 1999 Apr; 17(4):1155. PubMed ID: 10561174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ACR Appropriateness Criteria: Localized nodal indolent lymphoma.
    Hoppe BS; Hodgson DC; Advani R; Dabaja BS; Flowers CR; Ha CS; Metzger ML; Plastaras JP; Roberts KB; Shapiro R; Terezakis SA; Winkfield KM; Younes A; Constine LS
    Oncology (Williston Park); 2013 Aug; 27(8):786-94. PubMed ID: 24133827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose radiotherapy plus prolonged hormone therapy in CT2-3 prostatic carcinoma: is it useful?
    Cellini N; Pompei L; Fortuna G; Ammaturo MV; De Paula U; Luzi S; Mattiucci GC; Morganti AG; Digesù C; Rosetto ME; Palloni T; Petrongari MG; Gentile P; Deodato F; Valentini V
    Tumori; 2004; 90(2):201-7. PubMed ID: 15237583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
    Stokes SH
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACR Appropriateness Criteria prostate cancer--pretreatment detection, staging, and surveillance.
    Eberhardt SC; Carter S; Casalino DD; Merrick G; Frank SJ; Gottschalk AR; Leyendecker JR; Nguyen PL; Oto A; Porter C; Remer EM; Rosenthal SA
    J Am Coll Radiol; 2013 Feb; 10(2):83-92. PubMed ID: 23374687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACR Appropriateness Criteria® radiation therapy for small-cell lung cancer.
    Kong FM; Lally BE; Chang JY; Chetty IJ; Decker RH; Ginsburg ME; Kestin LL; Langer CJ; Movsas B; Videtic GM; Willers H; Rosenzweig KE;
    Am J Clin Oncol; 2013 Apr; 36(2):206-13. PubMed ID: 23511336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Definitive external beam irradiation in stage T1 and T2 carcinoma of the prostate. American College of Radiology. ACR Appropriateness Criteria.
    Perez CA; Beyer DC; Blasko JC; Forman JD; Hussey DH; Lee WR; Paryani SB; Pollack A; Potters L; Roach M; Scardino P; Schellhammer P; Leibel S
    Radiology; 2000 Jun; 215 Suppl():1449-72. PubMed ID: 11037559
    [No Abstract]   [Full Text] [Related]  

  • 38. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ACR Appropriateness Criteria®-Anal Cancer.
    ; Hong TS; Pretz JL; Herman JM; Abdel-Wahab M; Azad N; Blackstock AW; Das P; Goodman KA; Jabbour SK; Jones WE; Konski AA; Koong AC; Rodriguez-Bigas M; Small W; Thomas CR; Zook J; Suh WW
    Gastrointest Cancer Res; 2014 Jan; 7(1):4-14. PubMed ID: 24558509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.
    Roberts KB; Younes A; Hodgson DC; Advani R; Dabaja BS; Dhakal S; Flowers CR; Ha CS; Hoppe BS; Mendenhall NP; Metzger ML; Plastaras JP; Shapiro R; Smith SM; Terezakis SA; Winkfield KM; Constine LS;
    Am J Clin Oncol; 2016 Aug; 39(4):384-95. PubMed ID: 27299425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.